https://www.reuters.com/business/healthcare-pharmaceuticals/weight-loss-battle-novo-lilly-face-growing-offensive-licenced-copies-2024-12-20/
"Asked about the copies identified by Reuters, Eli Lilly said tirzepatide was a complex macromolecule that required rigorous testing.
“Any policies for approval of biosimilar products…present significant patient safety concerns. Regulators should proceed carefully, with patient safety at the forefront,” Lilly said in a written statement."
Of course they say that, that’s their goose that lays golden eggs
These protein-based drugs are pretty easy to make, that’s why these are available easily on grey market.
1 Like
KarlT
#3
Interesting story. I guess I had no idea that this was all legal and that countries were exempt from patent law.
I wonder how well the tablet forms work?
1 Like
Davin8r
#4
They don’t work (with the exception of branded Rybelsus tablets, of course).
KarlT
#5
Are you guessing or do you know this to be true?
Davin8r
#6
The molecules are too big for oral absorption, which is why Rybelsus has a patented penetration enhancer (called SNAC) that allows a small % of it to cross the stomach wall directly.
My wife and I also tried a compounded sublingual tirzepatide which had zero effect. Compounded oral versions would have taken over the market by now if they did anything.
2 Likes
